---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Conclusions"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Conclusions. 1 evidence topic quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary/conclusions"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

Cretostimogene grenadenorepvec is investigational; its safety and efficacy “have not been established by the FDA or any other health authority”. The rolling BLA, initiated in November 2025, is to include both CIS and high-grade papillary-only disease after FDA feedback, with completion anticipated in March 2027. No price has been announced.

The efficacy evidence comes from single-arm studies. In the phase 3 BOND-003 Cohort C, 83 of 110 participants (75.5%) had a complete response at any time as of the June 23, 2025 cutoff; landmark complete response was 46.4% at 12 months and 41.8% at 24 months, and median duration of response was 27.9 months. In Cohort P (papillary-only disease), estimated 9-month HG-EFS was 80.4% in 51 efficacy evaluable participants as of the September 1, 2025 cutoff. In the phase 2 CORE-001 trial with pembrolizumab, complete response at 12 months was 57.1% (20 of 35). Treatment-related adverse events occurred in 71 of 112 participants (63.4%) in Cohort C and 40 (71.4%) in Cohort P, none of grade 3 or higher.

The EAU guideline describes radical cystectomy as “the standard and preferred option”. Nadofaragene firadenovec, pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each evaluated in single-arm trials, with labeled complete response rates of 51%, 41%, 62%, and 82%, respectively.

No randomized comparison of cretostimogene with any of these options and no health-related quality of life results were identified. Only the abstract of the peer-reviewed Cohort C report could be quoted, and the prespecified statistical threshold was not found. For the same cutoff, company documents report 12- and 24-month duration of response of 64.2% and 60.1% in a 2026 presentation and 64.1% and 58.3% in the Form 10-K, and describe Cohort P as “an exploratory study” in the Form 10-K and as “currently not intended for regulatory approval” in a 2026 investor presentation.

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [Kissei Pharmaceutical Lancet Oncology publication press release (2026)](https://www.kissei.co.jp/news/uploaded/ac0d28038b8ced3e28ffd15df1f1d731.pdf); [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/); [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf); [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf); [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf); [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf); [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3); [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3); [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf); [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf); [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
